United Therapeutics (NASDAQ: UTHR) reported Q2 EPS of $6.41, $0.94 worse than the analyst estimate of $7.35. Revenue for the quarter came in at $798.6 million versus the consensus estimate of $804.98 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.